HALO — Halozyme Therapeutics Share News
0.000.00%
Last trade - 00:00- $13.79bn
- $15.71bn
- $1.40bn
Evotec soars 18% on 2 bln euro buyout offer
Evotec seen up on 2 bln euro buyout offer from Halozyme
Brief: Evotec Says Receives Non-Binding Takeover Offer From Halozyme At 11 Euros/Share
Deals of the day-Mergers and acquisitions
Halozyme makes 2 billion euro buyout offer for drug developer Evotec (updated)
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports
Brief: Germany's Evotec Gets Takeover Interest From Halozyme At About 11 Euros Per Share - Bloomberg News
Halozyme Therapeutics rises after raising FY forecast, upbeat Q3 results
U.S. STOCKS ON THE MOVE-Wayfair, B. Riley, Church & Dwight
U.S. STOCKS ON THE MOVE-Intel, Abbott, Boeing
Halozyme Therapeutics rises after raising FY forecast, upbeat Q3 results
Halozyme Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Halozyme Therapeutics Q3 Adjusted EPS USD 1.27 Vs. IBES Estimate USD 0.98
Halozyme Therapeutics falls after Wells Fargo downgrade
U.S. RESEARCH ROUNDUP-Athira pharma, Lowe's Companies, P&G
US FDA approves injectable version of Roche's multiple sclerosis therapy (updated)
US FDA approves injectable version of Roche's multiple sclerosis therapy
Brief: FDA Approves Ocrevus Zunovo For People With Relapsing And Progressive Multiple Sclerosis
Advisory: Stories on US FDA approving injectable Roche multiple sclerosis therapy are withdrawn